Literature DB >> 3084658

Mouse x human heterohybridomas as fusion partners with human B cell tumors.

W L Carroll, K Thielemans, J Dilley, R Levy.   

Abstract

Surface idiotype (Id) of B cell malignancies is an excellent tumor-specific marker. We have, however, recently described heterogeneity of tumor Id in some cases. We therefore sought a way to isolate, reliably and efficiently, different species of idiotype from a potentially heterogeneous population. In this report we demonstrate our success using a series of mouse X human heterohybridomas as fusion partners with human B cell tumors. Three lines (K6H6/B5, K6H9/G12, SBC/H20) demonstrated excellent fusion efficiency with 75%-85% of wells plated containing hybrids. Two cell lines, K6H9/G12 and SBC/H20 had a tendency to secrete a single Ig chain (heavy or light chain), whereas the K6H6/B5 cell line secreted whole immunoglobulin (Ig) in greater than 80% of the hybrids. This line secreted significant amounts of Ig (2.73 micrograms/ml/10(6) cells) and was relatively stable in culture. Since this line has such a high fusion efficiency the products of normal B cells admixed with tumor may be recovered, allowing the opportunity of isolating host anti-tumor antibodies. In order to prove that hybrids were derived from the tumor, Southern blot analysis of rearranged DNA was performed in selected cases. Fusions with this line provide the potential for recovering many different species of idiotype in a mixed population. This will facilitate the production of mouse monoclonal anti-idiotype antibodies against many variants and against different idiotopes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084658     DOI: 10.1016/0022-1759(86)90032-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  43 in total

1.  Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.

Authors:  Y Sun; M K Park; J Kim; B Diamond; A Solomon; M H Nahm
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

3.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

4.  Growth limitation in hybridoma cell cultures: the role of inhibitory or toxic metabolites.

Authors:  O W Rønning; M Schartum; A Winsnes; G Lindberg
Journal:  Cytotechnology       Date:  1991-09       Impact factor: 2.058

5.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

Review 6.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 7.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

8.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies.

Authors:  B Jansson; C A Borrebaeck
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.

Authors:  Soung-Chul Cha; Hong Qin; Shibichakravarthy Kannan; Seema Rawal; Leticia S Watkins; Flavio E Baio; Weiguo Wu; Juliana Ong; Jinsong Wei; Benjamin Kwak; Sang Kim; Michael S Popescu; Daniel S Paick; Kunhwa Kim; Amber Luong; Richard E Davis; Harry W Schroeder; Larry W Kwak; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.